COX-2 in liver,from regeneration to hepatocarcinogenesis:What we have learned from animal models?

被引:12
|
作者
Paloma Martín-Sanz [1 ,2 ]
Rafael Mayoral [1 ,2 ]
Marta Casado [1 ,3 ]
Lisardo Boscá [1 ,2 ]
机构
[1] Biomedical Network Center for the Study of Hepatic and Digestive Diseases(CIBERehd)
[2] Department of Metabolism and Cell Signaling,Institute of Biomedical Research "Alberto Sols"(CSIC-UAM)
[3] Department of Pathology and Molecular and Cellular Therapy,Institute of Biomedicine of Valencia(IBV-CSIC)
关键词
Cyclooxygenase; 2; Prostaglandins; Liver diseases; Apoptosis; Inflammation; Animal models;
D O I
暂无
中图分类号
R735.7 [肝肿瘤];
学科分类号
100214 ;
摘要
The use of animals lacking genes or expressing genes under the control of cell-specific promoters has signifi cantly increased our knowledge of the genetic and molecular basis of physiopathology,allowing testing of functional hypotheses and validation of biochemical and pharmacologic approaches in order to understand cell function.However,with unexpected frequency,gene knockout animals and,more commonly,animal models of transgenesis give experimental support to even opposite conclusions on gene function.Here we summarize what we learned on the role of cyclooxygenase 2(COX-2) in liver and revise the results obtained in 3 independent models of mice expressing a COX-2 transgene specifi cally in the hepatocyte.Upon challenge with pro-inflammatory stimuli,the animals behave very differently,some transgenic models having a protective effect but others enhancing the injury.In addition,one transgene exerts differential effects on normal liver physiology depending on the transgenic animal model used.
引用
收藏
页码:1430 / 1435
页数:6
相关论文
共 50 条
  • [31] Osteoarthritis pain: What are we learning from animal models?
    Miller, Rachel E.
    Malfait, Anne-Marie
    BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2017, 31 (05): : 676 - 687
  • [32] Cluster headache pathophysiology: What we have learned from advanced neuroimaging
    Silvestro, Marcello
    Tessitore, Alessandro
    Orologio, Ilaria
    Battista, Giorgia
    Siciliano, Mattia
    Tedeschi, Gioacchino
    Russo, Antonio
    HEADACHE, 2022, 62 (04): : 436 - 452
  • [33] What lessons have we learnt about the impact of maternal cigarette smoking from animal models?
    Chan, Yik L.
    Oliver, Brian G.
    Chen, Hui
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2020, 47 (02) : 337 - 344
  • [34] Food allergy: what do we learn from animal models?
    Knippels, Leon M. J.
    van Wijk, Femke
    Penninks, Andre H.
    CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY, 2004, 4 (03) : 205 - 209
  • [35] What have we learned recently from transgenic mouse models about neurodegeneration? The most promising discoveries of this millennium
    Kreiner, Grzegorz
    PHARMACOLOGICAL REPORTS, 2018, 70 (06) : 1105 - 1115
  • [36] Metabolomics in Psychiatric Disorders: What We Learn from Animal Models
    Humer, Elke
    Probst, Thomas
    Pieh, Christoph
    METABOLITES, 2020, 10 (02)
  • [37] NSAIDs and COX-2 inhibitors: what can we learn from large outcomes trials? The gastroenterologist's perspective
    Hawkey, CJ
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2001, 19 (06) : S23 - S30
  • [38] Animal Models for Dysphagia Studies: What Have We Learnt So Far
    German, Rebecca Z.
    Crompton, A. W.
    Gould, Francois D. H.
    Thexton, Allan J.
    DYSPHAGIA, 2017, 32 (01) : 73 - 77
  • [39] From vivarium to bedside: Lessons learned from animal models
    Budzynski, Ewa
    Lee, Yongsuk
    Sakamoto, Kenji
    Naggert, Juergen K.
    Nishina, Patsy M.
    OPHTHALMIC GENETICS, 2006, 27 (04) : 123 - 137
  • [40] COX-2: Separating myth from reality
    McKenna, F
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 1999, 28 : 19 - 29